| Dr Joseph Folsom Woodward, MD | |
|
12039 Ne 128th St Ste 500, Kirkland, WA 98034-3030 | |
| (425) 899-1287 | |
| Not Available |
| Full Name | Dr Joseph Folsom Woodward |
|---|---|
| Gender | Male |
| Speciality | Hand Surgery |
| Experience | 20 Years |
| Location | 12039 Ne 128th St Ste 500, Kirkland, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427169838 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2082S0105X | Plastic Surgery - Surgery Of The Hand | MD00046970 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Evergreenhealth Medical Center | Kirkland, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| King County Public Hospital District No 2 | 7618880097 | 481 |
News Archive
ZymoGenetics, Inc. today announced positive results from a Phase 2 clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. The trial met the primary endpoint of efficacy, as measured by objective response rate or lack of early disease progression. Overall response rate was 23.1%, in evaluable patients, and median progression-free survival was 4.3 months. The results were presented at the American Society of Clinical Oncology meeting.
A new study has revealed psoriatic arthritis may be activated by the same trigger in different patients. Researchers from the University of Oxford and the Wellcome Sanger Institute identified high levels of a specific receptor in immune cells from psoriatic arthritis patients, giving the strongest evidence yet of a single cause for the disease
Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory and cardiovascular disease areas and wound healing, announced today its results for the third quarter ended September 30, 2011.
A new drug is showing promise as a treatment for mesothelioma - one of the most lethal cancers of all.
Huntington's disease is an hereditary neurodegenerative disease featured by alterations in movement, cognitive deficiency and psychiatric disorders resulting from the degeneration of neurons in the striatum nucleus of the brain.
› Verified 2 days ago
| Entity Name | King County Public Hospital District No 2 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801986070 PECOS PAC ID: 7618880097 Enrollment ID: O20031111000557 |
News Archive
ZymoGenetics, Inc. today announced positive results from a Phase 2 clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. The trial met the primary endpoint of efficacy, as measured by objective response rate or lack of early disease progression. Overall response rate was 23.1%, in evaluable patients, and median progression-free survival was 4.3 months. The results were presented at the American Society of Clinical Oncology meeting.
A new study has revealed psoriatic arthritis may be activated by the same trigger in different patients. Researchers from the University of Oxford and the Wellcome Sanger Institute identified high levels of a specific receptor in immune cells from psoriatic arthritis patients, giving the strongest evidence yet of a single cause for the disease
Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory and cardiovascular disease areas and wound healing, announced today its results for the third quarter ended September 30, 2011.
A new drug is showing promise as a treatment for mesothelioma - one of the most lethal cancers of all.
Huntington's disease is an hereditary neurodegenerative disease featured by alterations in movement, cognitive deficiency and psychiatric disorders resulting from the degeneration of neurons in the striatum nucleus of the brain.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph Folsom Woodward, MD 12039 Ne 128th St Ste 500, Kirkland, WA 98034-3030 Ph: (425) 899-1287 | Dr Joseph Folsom Woodward, MD 12039 Ne 128th St Ste 500, Kirkland, WA 98034-3030 Ph: (425) 899-1287 |
News Archive
ZymoGenetics, Inc. today announced positive results from a Phase 2 clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. The trial met the primary endpoint of efficacy, as measured by objective response rate or lack of early disease progression. Overall response rate was 23.1%, in evaluable patients, and median progression-free survival was 4.3 months. The results were presented at the American Society of Clinical Oncology meeting.
A new study has revealed psoriatic arthritis may be activated by the same trigger in different patients. Researchers from the University of Oxford and the Wellcome Sanger Institute identified high levels of a specific receptor in immune cells from psoriatic arthritis patients, giving the strongest evidence yet of a single cause for the disease
Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory and cardiovascular disease areas and wound healing, announced today its results for the third quarter ended September 30, 2011.
A new drug is showing promise as a treatment for mesothelioma - one of the most lethal cancers of all.
Huntington's disease is an hereditary neurodegenerative disease featured by alterations in movement, cognitive deficiency and psychiatric disorders resulting from the degeneration of neurons in the striatum nucleus of the brain.
› Verified 2 days ago
Dr. Gavin M Dry, MD Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 13114 120th Ave Ne, Kirkland, WA 98034 Phone: 425-821-6000 Fax: 425-820-6288 |